BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the “Company”), a ...
TNF Pharmaceuticals (TNFA) announced that it has entered into a collaborative agreement with Renova Health for a planned trial of its TNF-alpha inhibitor drug isomyosamine as a treatment for ...
Genetic markers, specifically tumor necrosis factor alpha receptor 2 (TNFR2) gene polymorphisms, may predict response to TNF inhibitor therapy in patients with rheumatoid arthritis (RA). This approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback